# Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

> **NCT06431633** · PHASE3 · RECRUITING · sponsor: **Fundación GECP** · enrollment: 129 (estimated)

## Conditions studied

- Lung Diseases
- Carcinoma, Non-Small-Cell Lung
- Resectable Lung Non-Small Cell Carcinoma

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Sacituzumab govitecan
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06431633
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2031-11-30
- **Final completion:** 2031-11-30
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06431633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06431633, "Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT06431633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*